Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Am J Physiol Renal Physiol ; 295(2): F471-7, 2008 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-18524858

RESUMO

Peroxisome proliferator-activated receptor (PPAR) agonists were shown to inhibit atherosclerosis through augmentation of endothelial nitric oxide synthase (eNOS) activity. In addition, rosiglitazone exerts a beneficial effect in chronic renal failure (CRF). Since l-arginine transport by CAT-1 (the specific arginine transporter for eNOS) is inhibited in uremia, we aimed to explore the effect of rosiglitazone on arginine transport in CRF. Arginine uptake by aortic rings was studied in control animals, rats, 6 wk following 5/6 nephrectomy (CRF) and rats with CRF treated with rosiglitazone. The decrease of arginine transport in CRF was prevented by rosiglitazone. Immunobloting revealed that CAT-1 protein was decreased in CRF but remained unchanged following rosiglitazone administration. Protein content of the membrane fraction of PKCalpha and phosphorylated CAT-1 increased significantly in CRF, effects that were prevented by rosiglitazone. PKCalpha phosphorylation was unchanged but significantly attenuated by rosiglitazone in CRF. Ex vivo administration of phorbol-12-myristate-13-acetate to rosiglitazone-treated CRF rats significantly attenuated the effect of rosiglitazone on arginine uptake. The decrease in cGMP response to carbamyl-choline (eNOS agonist) was significantly attenuated by rosiglitazone in CRF. Western blotting and immunohistochemistry analysis revealed that protein nitration was intensified in the endothelium of CRF rats and this was attenuated by rosiglitazone. In conclusion, rosiglitazone prevents the decrease in arginine uptake in CRF through both depletion and inactivation of PKCalpha. These findings are associated with restoration of eNO generation and attenuation of protein nitration and therefore may serve as a novel mechanism to explain the beneficial effects of rosiglitazone on endothelial function in uremia.


Assuntos
Aorta/metabolismo , Arginina/metabolismo , Hipoglicemiantes/farmacologia , Proteína Quinase C-alfa/antagonistas & inibidores , Tiazolidinedionas/farmacologia , Uremia/metabolismo , Animais , Transporte Biológico/efeitos dos fármacos , Transportador 1 de Aminoácidos Catiônicos/metabolismo , Modelos Animais de Doenças , Falência Renal Crônica/metabolismo , Masculino , Óxido Nítrico/metabolismo , Proteína Quinase C-alfa/efeitos dos fármacos , Proteína Quinase C-alfa/metabolismo , Ratos , Ratos Wistar , Rosiglitazona
2.
Kidney Blood Press Res ; 31(3): 210-6, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18552509

RESUMO

BACKGROUND: The decrease in glomerular filtration rate (GFR), which is characteristic of obstructive uropathy, was suggested to be associated with attenuated nitric oxide (NO) generation. Since availability of L-arginine, the sole precursor for NO, governs NO synthesis, we aimed to determine the role of glomerular arginine transport in rats subjected to 24 h of bilateral ureteral ligation (BUO). METHODS: Glomerular arginine transport was measured by uptake of radiolabeled arginine ([(3)H]-L-arginine), cationic amino acid transporters (CAT)-1 and -2 and arginases I and II mRNA expression were determined using reverse transcription-polymerase chain reaction. CAT-1, arginase I, and arginase II protein contents were evaluated by Western blotting. RESULTS: L-Arginine transport by freshly harvested glomeruli from BUO rats was significantly augmented than in controls. The aforementioned findings were associated with a significant increase in glomerular CAT-1 mRNA expression, while CAT-2 mRNA was unchanged. Western blotting demonstrated a significant increase in CAT-1 abundance in BUO. Expression of both glomerular arginase I and II mRNA and protein content were significantly elevated in BUO. CONCLUSIONS: BUO induces an increase in glomerular arginine transport via upregulation of CAT-1, probably due to increase in arginine utilization by a non-NO pathway.


Assuntos
Arginina/metabolismo , Transportador 1 de Aminoácidos Catiônicos/análise , Regulação da Expressão Gênica , Nefropatias/metabolismo , Animais , Arginase/análise , Arginase/genética , Transporte Biológico , Transportador 1 de Aminoácidos Catiônicos/genética , Transportador 2 de Aminoácidos Catiônicos/análise , Transportador 2 de Aminoácidos Catiônicos/genética , Modelos Animais de Doenças , RNA Mensageiro/análise , Ratos
3.
Atherosclerosis ; 185(2): 406-12, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16046220

RESUMO

The objective of the study was to evaluate the association between heart valve calcification and atherosclerosis and outcome in systemic lupus erythematosus (SLE). One-hundred and seven patients with SLE (mean age 45.9 +/- 14.7 years) were studied by 2D transthoracic echocardiography. Mitral annulus calcification (MAC) was detected in 24 patients (22.6%) and aortic valve calcification (AVC) in 22 (20.1%). Both MAC and AVC were associated with older age (r = 0.2, p = 0.02; r = 0.40, p

Assuntos
Aterosclerose/complicações , Calcinose/complicações , Doenças das Valvas Cardíacas/complicações , Lúpus Eritematoso Sistêmico/complicações , Valva Aórtica/diagnóstico por imagem , Calcinose/diagnóstico por imagem , Causas de Morte , Ecocardiografia , Feminino , Doenças das Valvas Cardíacas/diagnóstico por imagem , Humanos , Masculino , Pessoa de Meia-Idade , Valva Mitral/diagnóstico por imagem , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...